Cancer

October 21, 2019

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 21/October/2019, 10.31 pm

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, […]
October 12, 2019

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1,  p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 13/October/2019, 12.55 am

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, […]
October 4, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib,  Letrozole  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls advanced breast cancer  progression, via up-regulation of its target gene, 5/October/2019, 1.00 am

Introduction: What they say A study from Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los […]
September 19, 2019

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in metastatic breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib,  Fulvestrant and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1 and CADM1/2,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls metastatic breast cancer  progression, via up-regulation of its target gene, 19/September/2019, 10.29 pm

Introduction: What they say A study from Institute of Cancer Research and Royal Marsden Hospital, London, David Geffen School of Medicine at University of California, Los Angeles, Santa […]